Adoptive therapy with chimeric antigen receptor-modified T cells of defined subset composition.
about
CAR T Cell Therapy: A Game Changer in Cancer TreatmentCAR therapy: the CD19 paradigmManufacture of tumor- and virus-specific T lymphocytes for adoptive cell therapiesSmart CARs engineered for cancer immunotherapyEqual opportunity CAR T cells.Progress and prospects of gene therapy clinical trials for the muscular dystrophies.Switch-mediated activation and retargeting of CAR-T cells for B-cell malignancies.A High-avidity WT1-reactive T-Cell Receptor Mediates Recognition of Peptide and Processed Antigen but not Naturally Occurring WT1-positive Tumor Cells.CD19 CAR-T cells of defined CD4+:CD8+ composition in adult B cell ALL patientsThe Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of hematologic malignancies: multiple myeloma, lymphoma, and acute leukemia.CCR7+ selected gene-modified T cells maintain a central memory phenotype and display enhanced persistence in peripheral blood in vivo.Global Manufacturing of CAR T Cell Therapy.Going viral: chimeric antigen receptor T-cell therapy for hematological malignancies.CD19 chimeric antigen receptor T cell therapy for haematological malignancies.New cell sources for T cell engineering and adoptive immunotherapy.CAR T-cell immunotherapy: The path from the by-road to the freeway?Establishing guidelines for CAR-T cells: challenges and considerations.Cell-Mediated Immunity to Target the Persistent Human Immunodeficiency Virus Reservoir.Chimeric antigen receptors: driving immunology towards synthetic biology.Current modalities in cancer immunotherapy: Immunomodulatory antibodies, CARs and vaccines.Comprehensive Approach for Identifying the T Cell Subset Origin of CD3 and CD28 Antibody-Activated Chimeric Antigen Receptor-Modified T Cells.Enhanced CAR T-cell engineering using non-viral Sleeping Beauty transposition from minicircle vectors.Chimeric-antigen receptor T (CAR-T) cell therapy for solid tumors: challenges and opportunities.Cancer Immunotherapy Using CAR-T Cells: From the Research Bench to the Assembly Line.Inhibition of AKT signaling uncouples T cell differentiation from expansion for receptor-engineered adoptive immunotherapy.Tumor-Specific T-Cells Engineered to Overcome Tumor Immune Evasion Induce Clinical Responses in Patients With Relapsed Hodgkin Lymphoma.Prospects to improve chimeric antigen receptor T-cell therapy for solid tumors.Trial Watch: Adoptively transferred cells for anticancer immunotherapy.
P2860
Q26822769-BCAC9D07-BCCA-42E5-B19C-B2EA3CAA9443Q28081642-228EB1A8-5303-4BA5-AD47-C9544757817CQ28085769-D8D0ED3E-ECE0-48F6-851A-0BB115FE5613Q28087236-AD0FC89C-1836-477A-89CF-66FD414845A6Q33828001-110FD9C6-020A-4643-A9CB-6B322A78A450Q34497471-B36BABBB-3630-4FD0-8034-507D670BD7C4Q36551673-38CF4BC9-1872-430E-AD50-3547A7F70CA2Q36943923-371BF25E-5510-4519-B7CC-3B17FD3F8EC9Q36951727-8FB799E3-8743-45D8-A948-A791DD55B890Q37517482-F61B60F2-D778-4D41-9A0A-F1DC8D495894Q37655544-425C7982-51E5-4460-9D9C-1FAE8C3202F2Q37717884-D1FA3FB6-267F-4E1C-BE15-E36DC6B19A82Q38289029-25026B4D-0F33-43D8-B830-6C44A98560EAQ38370975-F308EC36-CC8B-4AF5-97B4-3BEB07C25AA6Q38406089-3BDB9BB5-380D-46F8-B6B7-5095885FE96EQ38632105-8A420E5F-CDF6-4B00-BCAB-39F60441A2A9Q38769264-5534FBE9-4D9E-4040-8435-BDB8636CE7B6Q38777005-B08B9840-A625-4848-9D34-453B6F51E634Q38884383-697C7DC4-48C1-4382-9E23-FAF249B15B89Q39189908-2B1EA9DE-FA06-46BE-8B8E-C7D47FA652E9Q40183378-B2F44EC1-36F9-4F2D-AE18-A1C3BFD446A0Q40635962-F1298C04-5C7E-4938-9C0A-1586433EE992Q45832774-368B2599-F816-409B-84A1-8C3CCFE2B476Q45872592-09147328-FF39-40C4-AD84-14E4BD8B7C96Q45875529-9F99D328-88AE-4EEB-AF2B-BBB49C83E7A7Q47218634-F6CDA5DF-984A-4A44-996E-DBE97D12166BQ50035774-2E8D468D-0E51-4A94-9172-C3545DB429B6Q52780137-F552EB18-00F3-4C28-BBCC-99A7694C96C9
P2860
Adoptive therapy with chimeric antigen receptor-modified T cells of defined subset composition.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Adoptive therapy with chimeric ...... of defined subset composition.
@en
type
label
Adoptive therapy with chimeric ...... of defined subset composition.
@en
prefLabel
Adoptive therapy with chimeric ...... of defined subset composition.
@en
P2093
P2860
P1433
P1476
Adoptive therapy with chimeric ...... of defined subset composition.
@en
P2093
Alex Salter
Ashwini Balakrishnan
Cameron J Turtle
Carolina Berger
Daniel Sommermeyer
Lingfeng Steven Liu
Stanley R Riddell
P2860
P304
P356
10.1097/PPO.0000000000000036
P577
2014-03-01T00:00:00Z